Stockscreener 앱 받기
4.01
0.25%
-0.010
Design Therapeutics Inc 주식(DSGN)의 최신 뉴스
What analysts say about Design Therapeutics Inc. stockConsistent high-performance stocks - Jammu Links News
What drives Design Therapeutics Inc. stock priceConsistently high returns - Jammu Links News
Design Therapeutics (NASDAQ:DSGN) Stock Price Down 3.1% – Should You Sell? - Defense World
Is Design Therapeutics Inc. stock a growth or value playFree Stock Market Swing Trading Strategies - Newser
Why Design Therapeutics Inc. stock attracts strong analyst attentionDefensive Stock Picks with Upside - beatles.ru
Why Synaptogenix Inc. stock attracts strong analyst attentionSecure Your Capital Strategy - Newser
What makes Design Therapeutics Inc. stock price move sharplyDaily Breakout Picks - Newser
Why Sionna Therapeutics Inc. stock attracts strong analyst attentionFree VIP Investment Strategies - Newser
How Design Therapeutics Inc. stock performs during market volatilityElite Stock Shortlist - Newser
High-Potential Biotech Penny Stocks in 2025: ProKidney and Design Therapeutics Lead the Way - AInvest
Penny Stocks To Watch In July 2025 - simplywall.st
Maze Therapeutics Soars 11.68% on Wedbush's Outperform Rating - AInvest
BioVie Highlights Patient-Centric Design of SUNRISE-PD - GlobeNewswire
FDA Boosts CERo's Revolutionary T Cell Therapy with Orphan Drug Status for Deadly Blood Cancer - Stock Titan
Design Therapeutics Confirms Directors at Annual Meeting - TipRanks
Design Therapeutics reports voting results from annual meeting - Investing.com
Squarepoint Ops LLC Has $297,000 Position in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Friedreich's Ataxia Market Poised for Rapid Expansion During the Forecast Period (2025-2034) as Drug Pipeline Gains Momentum | DelveInsight - The Malaysian Reserve
BNP Paribas Financial Markets Makes New Investment in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World
Nuveen Asset Management LLC Sells 54,550 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Two Sigma Investments LP Trims Stock Holdings in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Millennium Management LLC Acquires New Shares in OnKure Therapeutics (NASDAQ:OKUR) - Defense World
Design Therapeutics starts Friedreich ataxia patient trial By Investing.com - Investing.com South Africa
Transcript : Design Therapeutics, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 02 - marketscreener.com
RBC Capital maintains Design Therapeutics stock rating with $5 target - Investing.com Australia
RBC Capital maintains Design Therapeutics stock rating with $5 target By Investing.com - Investing.com South Africa
Design Therapeutics (DSGN) Advances Friedreich Ataxia Clinical T - GuruFocus
Design Therapeutics starts Friedreich ataxia patient trial - Investing.com
Design Therapeutics Announces Start Of Friedreich Ataxia Patient Dosing Ex-U.S. In Its Restore-Fa Phase 1/2 Multiple-Ascending Dose Trial Of Dt-216P2 - marketscreener.com
Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2 - The Manila Times
Design Therapeutics, Inc. Reports Initial Safety Data for DT-216P2 in Friedreich Ataxia Trial Amid FDA Clinical Hold on U.S. IND Application - Nasdaq
Design Therapeutics Achieves First Patient Dosing in Friedreich Ataxia Trial, Faces FDA Hurdle - Stock Titan
ProShare Advisors LLC Makes New $71,000 Investment in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Bank of America Corp DE Sells 556,157 Shares of Aegon Ltd. (NYSE:AEG) - Defense World
40,289 Shares in Design Therapeutics, Inc. (NASDAQ:DSGN) Acquired by BNP Paribas Financial Markets - Defense World
Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference - TradingView
Clinical-Stage Biotech Design Therapeutics Set for Major Jefferies Healthcare Conference Presentation - Stock Titan
Autodesk (NASDAQ:ADSK) Price Target Raised to $376.00 at Citigroup - Defense World
Myotonic Dystrophy Market to Expand Significantly by 2034, - openPR.com
As Gold Pushes Higher, Junior Miners Begin to Show Signs of Life - The Globe and Mail
Palantir vs. IBM: The Breakthrough Wall Street Is Missing - The Globe and Mail
Is Pfizer Stock a Buy After This $1.25 Billion Investment? - The Globe and Mail
Northern Trust Corp Purchases 51,351 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
3 Penny Stocks With Market Caps As Low As $70M To Watch - Yahoo Finance
Scratch That? De Novo Antibody Design Enters the AI Drug Discovery Toolbox - Genetic Engineering and Biotechnology News
0.86%
0.10%
자본화:
|
볼륨(24시간):